Nama's AI scorecard currently rates Personalis Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PSNL report earnings?

Personalis's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.25.

What is the PSNL price target?

The median analyst price target from 3 analysts is $16.25, with a range of $13.00 – $16.25.

Is PSNL Shariah compliant?

Nama's AAOIFI-style screen reads Personalis as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Personalis (PSNL)

Healthcare · Diagnostics Research · NASDAQ

Personalis (PSNL) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.71B and a free-cash-flow yield of -5.6%. Over the most recent reported fiscal year, revenue declined 17.7%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.5/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +122.7% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-25.4%

How far the last close sits under the highest price of the past five years.

Market cap	$1.71B
Trailing P/E	—
Price / book	7.1
Price / sales	24.3
FCF yield	-5.6%
Dividend yield	—
Gross margin	12.7%
Operating margin	-164.1%
Net margin	-153.8%
Revenue growth (YoY)	-17.7%
Revenue growth (3-yr annual)	+2.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

PSNL earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.25). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 4, 2026	-$0.30	-$0.28	-7.1%	$22.36M
Q1 2026	May 7, 2026	-$0.29	-$0.28	-3.6%	$15.47M
Q4 2025	Feb 26, 2026	-$0.26	-$0.28	+7.1%	$17.34M
Q3 2025	Nov 4, 2025	-$0.24	-$0.27	+11.1%	$14.49M

PSNL analyst price target

Median target $16.25 from 3 analysts, ranging $13.00 – $16.25.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live PSNL data on Nama Insights →

PSNL FAQ

Is PSNL a buy?: Nama's AI scorecard currently rates Personalis Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PSNL report earnings?: Personalis's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.25.
What is the PSNL price target?: The median analyst price target from 3 analysts is $16.25, with a range of $13.00 – $16.25.
Is PSNL Shariah compliant?: Nama's AAOIFI-style screen reads Personalis as Not Shariah Compliant. At least one of the three ratios or the industry test failed.